News Releases

GAITHERSBURG, Md. and SHANGHAI , June 23, 2022 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies

SHANGHAI and GAITHERSBURG, Md. , June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner

SHANGHAI and GAITHERSBURG, Md. , May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinical

-  Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity -  Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort -  Results indicate CD73 expression correlates with clinical

SHANGHAI and GAITHERSBURG, MD . , May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m.

SHANGHAI and GAITHERSBURG, Md. , May 5, 2022 /PRNewswire/ -- I-Mab (" I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding

SHANGHAI, China and GAITHERSBURG, MD. , April 29, 2022 (PRNewswire) — I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company has filed its annual

-  Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO -  Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and

SHANGHAI and GAITHERSBURG, Md. , March 31, 2022 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC

Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab Seven business development deals, including a US$315M strategic commercial partnership with Jumpcan on